The botulinum neurotoxins, BoNTs, produced by Clostridium botulinum are among the most potent toxins known to man. The Centers for Disease Control and Prevention (CDC) has classified it as a potential bioweapon, Category A, because of its extreme potency and lethality, its ease of production and transport, and the need for prolonged intensive care among affected persons. This project participates on a collaboration focusing on the various serotypes and subtypes of the toxin with the overall goal of characterizing these variants at the DMA and protein level and developing a deeper understanding of neurotoxin action. We will focus on three major research areas: (1) continuing to deepen our understanding of the cell receptor recognition and binding processes as well as the translocation process by determining the structures of the toxin in complex with cell recognition receptor molecules, (2) developing a detailed understanding on how the recently developed antibodies (Abs), work and how we can then improve them, and (3) using structurebased approaches engineer the next generation broad spectrum diagnostic antibodies (working towards one antibody to recognize multiple toxin subtypes and serotypes). The study will characterize a number of BoNT variants to assess their impact on the development of diagnostics and therapeutics and to understand differences in biological action. In addition to the structures, the project will also produce highly purified protein samples that will be made available to its collaborators and other workers in the biodefense consortium.
We will structurally characterize botulinum neurotoxins (BoNTs);the most potent toxins known to man and classified as potential bio-weapon, category A by CDC. Variants have been identified and antibodies were shown to be ineffective across subtypes. Diagnostics and therapeutics development including the numerous and widely used medical applications that utilize the toxin (e.g., dystonia, chronic pain, neuromuscular disorders) will benefit from a deeper understanding of toxin action.
|Torres, Rodrigo; Lan, Benson; Latif, Yama et al. (2014) Structural snapshots along the reaction pathway of Yersinia pestis RipA, a putative butyryl-CoA transferase. Acta Crystallogr D Biol Crystallogr 70:1074-85|
|Houghton, Raymond L; Reed, Dana E; Hubbard, Mark A et al. (2014) Development of a prototype lateral flow immunoassay (LFI) for the rapid diagnosis of melioidosis. PLoS Negl Trop Dis 8:e2727|
|Strotmeier, Jasmin; Mahrhold, Stefan; Krez, Nadja et al. (2014) Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A. FEBS Lett 588:1087-93|
|Koellhoffer, Jayne F; Dai, Zhou; Malashkevich, Vladimir N et al. (2014) Structural characterization of the glycoprotein GP2 core domain from the CAS virus, a novel arenavirus-like species. J Mol Biol 426:1452-68|
|Bennett, Shannon N; Gu, Se Hun; Kang, Hae Ji et al. (2014) Reconstructing the evolutionary origins and phylogeography of hantaviruses. Trends Microbiol 22:473-82|
|Burtnick, Mary N; Brett, Paul J; DeShazer, David (2014) Proteomic analysis of the Burkholderia pseudomallei type II secretome reveals hydrolytic enzymes, novel proteins, and the deubiquitinase TssM. Infect Immun 82:3214-26|
|Koskiniemi, Sanna; Garza-Sánchez, Fernando; Sandegren, Linus et al. (2014) Selection of orphan Rhs toxin expression in evolved Salmonella enterica serovar Typhimurium. PLoS Genet 10:e1004255|
|Sabouri, Amir H; Marcondes, Maria Cecilia Garibaldi; Flynn, Claudia et al. (2014) TLR signaling controls lethal encephalitis in WNV-infected brain. Brain Res 1574:84-95|
|Vigant, Frederic; Hollmann, Axel; Lee, Jihye et al. (2014) The rigid amphipathic fusion inhibitor dUY11 acts through photosensitization of viruses. J Virol 88:1849-53|
|Relman, David A (2014) "Inconvenient truths" in the pursuit of scientific knowledge and public health. J Infect Dis 209:170-2|
Showing the most recent 10 out of 317 publications